8 results on '"Flori, Maria"'
Search Results
2. Effect of dupilumab on sleep disturbances in adult patients with severe atopic dermatitis.
- Author
-
Milanesi N, Gola M, Cartocci A, Tronconi G, Bruzziches F, Flori ML, Rubegni P, and Russo F
- Subjects
- Adult, Antibodies, Monoclonal, Humanized, Female, Humans, Infant, Male, Middle Aged, Pruritus drug therapy, Retrospective Studies, Sleep, Treatment Outcome, Dermatitis, Atopic complications, Sleep Wake Disorders drug therapy
- Abstract
Background: Sleep disturbances are common in patients with atopic dermatitis (AD). Considering their relevant burden on health, routine screening of sleep disturbances seems to be very useful in AD adults' management. However, few studies have evaluated the association between sleep disturbances and AD in adults, and real-life data are lacking. The aim of this study was to assess the effect of treatment with dupilumab on sleep disturbances in adult patients with severe atopic dermatitis., Methods: This is a retrospective, multicenter study including patients (age ≥18 y) with severe atopic dermatitis treated with dupilumab for at least 8 months from January 2019 to January 2020. Patients were evaluated three times: at treatment initiation (T0), at 4 (T4) and 8 months (T8) from the start of treatment. At each visit disease activity was assessed by severity score (Eczema Area and Severity Index [EASI]), patient-reported outcomes (Pruritus Numerical Rating Scale [NRS], Dermatology Life Quality Index [DLQI], and Pittsburgh Sleep Quality Index [PSQI]). Kolmogorov-Smirnov Test was performed to evaluate the normality distribution, Bartlett's Test for homoscedasticity. Since the assumptions were met, ANOVA for repeated measures was performed to evaluate the mean difference of PSQI, EASI, DLQI and pruritus NRS between baseline, the 4
th month and the 8th month. In addition, χ2 for Trend Test was performed to evaluate the increasing/decreasing prevalence of poor sleepers., Results: A total of 36 patients (15 females and 21 males) with a mean age of 42.5±14.3 (range 20-67) were included in the study. The mean score for PSQI at TO was 9.0±3.6. At week 16 (T4) the mean score for PSQI was 4.92±2.99 and at week 32 (T8), the mean score for PSQI was 4.3±3.0. EASI, NRS pruritus and DLQI significantly improved during follow-up (P<0.001) whereas PSQI improved significantly at 16 weeks (T4); however, no significant further improvement was observed at 32 weeks. Of the 31 patients (86%) with baseline PSQI≥5, 17 (54%) experienced sleep quality improvement during treatment. Overall, we observed a total of 22 patients (61.1%) having a PSQI<5 at 32 weeks., Conclusions: Our data show effectiveness of dupilumab in improving sleep disturbances in adult patients with severe AD. However, further studies are required to understand if PSQI could serve as useful evaluating tool.- Published
- 2022
- Full Text
- View/download PDF
3. Dupilumab in Elderly Patients With Severe Atopic Dermatitis.
- Author
-
Russo F, Milanesi N, Cartocci A, Bruzziches F, Tronconi G, Lazzeri L, D'erme AM, Bagnoni G, Gola M, Cinotti E, Rubegni P, and Flori ML
- Subjects
- Adult, Age Factors, Aged, Dermatitis, Atopic diagnosis, Humans, Male, Quality of Life, Retrospective Studies, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Dermatitis, Atopic drug therapy, Severity of Illness Index
- Abstract
Background: Atopic dermatitis (AD) in the elderly has been poorly investigated, although its incidence is gradually increasing mainly in industrialized countries. Age-specific factors in older patients must be considered when selecting treatment options., Objectives: To evaluate the efficacy and tolerability of dupilumab in treating elderly patients with severe AD., Methods: This was a retrospective, multicenter study involving 26 elderly patients (age, ≥65 years) with severe AD who were treated with dupilumab for at least 16 weeks. Absolute and percentage frequencies were used to evaluate qualitative variables and mean and SD for quantitative ones. For Eczema Area and Severity Index (EASI), Pruritus Numeric Rating Scale (NRS), and Dermatology Life Quality Index (DLQI), the median was also calculated. Wilcoxon test was used to evaluate the variations in EASI, Pruritus NRS, and DLQI observed between the 2 examinations., Results: After 4 months of therapy, the majority of patients showed a significant improvement in EASI (64.4%), Pruritus NRS (58.2%), and DLQI (44.9%). Only 11% of patients reported mild or moderate conjunctivitis., Conclusions: To the best of our knowledge, this is the first study concerning the use of dupilumab in the elderly with severe AD. Our data show the effectiveness of dupilumab in this particular population with a lower percentage of conjunctivitis than observed in studies on adults and also excellent control of itching. Only larger, controlled case studies will be able to clarify whether the dosage or frequency of administration of dupilumab in these patients should be different from the protocol used for adults., Competing Interests: The authors have no funding or conflicts of interest to declare., (Copyright © 2020 American Contact Dermatitis Society. All Rights Reserved.)
- Published
- 2021
- Full Text
- View/download PDF
4. Impact of dupilumab discontinuation in a patient with atopic prurigo.
- Author
-
Milanesi N, Tronconi G, Gola M, Flori ML, and Russo F
- Subjects
- Antibodies, Monoclonal, Humanized, Humans, Dermatitis, Atopic drug therapy, Prurigo drug therapy
- Published
- 2021
- Full Text
- View/download PDF
5. Severe Adult Atopic Dermatitis: Clinical Challenges.
- Author
-
Russo F, Flori ML, Gola M, and Milanesi N
- Subjects
- Adult, Antibodies, Monoclonal, Humanized immunology, Dermatitis, Atopic immunology, Dermatologic Agents immunology, Humans, Severity of Illness Index, Antibodies, Monoclonal, Humanized therapeutic use, Dermatitis, Atopic diagnosis, Dermatitis, Atopic drug therapy, Dermatologic Agents therapeutic use
- Published
- 2020
- Full Text
- View/download PDF
6. Tuscan Consensus on the diagnosis, treatment and follow up of adult atopic dermatitis.
- Author
-
Russo F, Milanesi N, Iannone M, Bagnoni G, Bartoli L, Bellini M, Brandini L, Buggiani G, Cecchi R, Cuccia A, D'erme AM, Dini V, Gori A, Grazzini M, Marsili F, Masci G, Mazzoli S, Peccianti C, Pellegrino M, Pimpinelli N, Rubegni P, Taviti F, Tedeschi C, Tonini G, Mazzatenta C, Flori ML, and Gola M
- Subjects
- Adult, Dermatitis, Atopic diagnosis, Dermatitis, Atopic pathology, Humans, Severity of Illness Index, Dermatitis, Atopic therapy, Interdisciplinary Communication
- Abstract
Atopic dermatitis (AD) is an inflammatory disease with a chronic-relapsing course that is intensely itchy. A correct diagnosis of AD in adults and consequently appropriate clinical therapeutic management is a critical issue for extreme clinical expression heterogeneity and various grades of disease severity. In order to ensure high levels of care and standardization of clinical therapeutic management of Adult AD, the decision was taken to create an AD Tuscan Consensus Group (the Group), to work on and validate a consensus based regional clinical-therapeutic management model. The aims of the Group were to find agreement on the criteria for diagnosis, scoring of severity, multidisciplinary approach and treatment of adult atopic dermatitis and to create an easier way for patients to access specialized dermatology outpatient services and importantly to reduce waiting lists and costs related to the management of AD. The Tuscan Consensus Group adopted a simplified Delphi method, in three principal steps: 1) literature metanalysis and critical review of patient's clinical experience to identify the main areas considered questionable or uncertain; 2) discussion of those areas requiring consensus and statement definition through four different sub-committees (diagnosis, severity evaluation, scoring and comorbidities); 3) a consensus based simplified process with final approval of each statement by plenary vote with approval >80% of the participants. The Group here presents and discusses the consensus based recommendation statements on adult atopic dermatitis.
- Published
- 2020
- Full Text
- View/download PDF
7. Efficacy of Dupilumab in two patients with severe and recalcitrant atopic dermatitis previously treated with extracorporeal photopheresis.
- Author
-
Russo F, Taddeucci P, Lazzeri L, Flori ML, and Rubegni P
- Subjects
- Adult, Antibodies, Monoclonal, Humanized, Humans, Interleukin-13, Dermatitis, Atopic diagnosis, Dermatitis, Atopic drug therapy, Photopheresis
- Abstract
Atopic dermatitis (AD) is a complex disease and can often be a clinical challenge for dermatologists. When standard immunosuppressive therapies fail, extracorporeal phototherapy (ECP) can be considered as a therapeutic option. In recent years, better understanding of the pathogenesis of AD allowed to improve treatment strategies with many emerging therapeutic options. Currently, Dupilumab, a monoclonal antibody that selectively inhibits IL-4 and IL-13, is the only biological drug authorized for the treatment of severe adult atopic dermatitis, refractory to traditional firstline and secondline therapies. ECP, compared to biological therapy, is associated with some disadvantages: it is costly and time-consuming for patients and personnel to administer. Moreover, it should be noted that the completion of the entire procedure takes about 3 hr and must be done in a hospital, while the administration of Dupilumab can be carried out by patients themselves at home. For these reasons and on the basis of our experience, it would be necessary to evaluate whether all patients with refractory atopic dermatitis in treatment with ECP with unsatisfactory clinical response should be switched to recent available target therapies., (© 2020 Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
8. Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines
- Author
-
Altomare, G., Ayala, F., Bardazzi, F., Bellia, G., Chimenti, S., Colombo, D., Flori, M. L., Girolomoni, G., Giuseppe MICALI, Parodi, A., Peris, K., Vena, G. A., Altomare, Gianfranco, Ayala, Fabio, Bardazzi, Federico, Bellia, Gilberto, Chimenti, Sergio, Colombo, Delia, Flori, Maria L, Girolomoni, Giampiero, Micali, Giuseppe, Parodi, Aurora, Peris, Ketty, and Vena, Gino A.
- Subjects
Adult ,Europe ,Skin diseases ,Italy ,Practice Guidelines as Topic ,Cyclosporine ,Psoriasis ,Humans ,Dermatologic Agents ,Child ,Immunosuppressive Agents ,Dermatitis, Atopic - Abstract
Cyclosporine (CsA) is an effective and safe therapeutic option in various dermatoses in both adults and children. Over the last 25 years, Italian dermatologists have gained relevant experience about the use of CsA in the treatment of psoriasis and atopic dermatitis, and an Italian Consensus Conference has recently provided recommendations in adult patients. A comparison between these real-world indications and current European guidelines is hereby provided.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.